Cargando…

Multistep, effective drug distribution within solid tumors

The distribution of drugs within solid tumors presents a long-standing barrier for efficient cancer therapies. Tumors are highly resistant to diffusion, and the lack of blood and lymphatic flows suppresses convection. Prolonged, continuous intratumoral drug delivery from a miniature drug source offe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shemi, Amotz, Khvalevsky, Elina Zorde, Gabai, Rachel Malka, Domb, Abraham, Barenholz, Yechezkel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741846/
https://www.ncbi.nlm.nih.gov/pubmed/26416413
_version_ 1782414083486646272
author Shemi, Amotz
Khvalevsky, Elina Zorde
Gabai, Rachel Malka
Domb, Abraham
Barenholz, Yechezkel
author_facet Shemi, Amotz
Khvalevsky, Elina Zorde
Gabai, Rachel Malka
Domb, Abraham
Barenholz, Yechezkel
author_sort Shemi, Amotz
collection PubMed
description The distribution of drugs within solid tumors presents a long-standing barrier for efficient cancer therapies. Tumors are highly resistant to diffusion, and the lack of blood and lymphatic flows suppresses convection. Prolonged, continuous intratumoral drug delivery from a miniature drug source offers an alternative to both systemic delivery and intratumoral injection. Presented here is a model of drug distribution from such a source, in a multistep process. At delivery onset the drug mainly affects the closest surroundings. Such ‘priming’ enables drug penetration to successive cell layers. Tumor ‘void volume’ (volume not occupied by cells) increases, facilitating lymphatic perfusion. The drug is then transported by hydraulic convection downstream along interstitial fluid pressure (IFP) gradients, away from the tumor core. After a week tumor cell death occurs throughout the entire tumor and IFP gradients are flattened. Then, the drug is transported mainly by ‘mixing’, powered by physiological bulk body movements. Steady state is achieved and the drug covers the entire tumor over several months. Supporting measurements are provided from the LODER™ system, releasing siRNA against mutated KRAS over months in pancreatic cancer in-vivo models. LODER™ was also successfully employed in a recent Phase 1/2 clinical trial with pancreatic cancer patients.
format Online
Article
Text
id pubmed-4741846
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-47418462016-03-23 Multistep, effective drug distribution within solid tumors Shemi, Amotz Khvalevsky, Elina Zorde Gabai, Rachel Malka Domb, Abraham Barenholz, Yechezkel Oncotarget Research Paper The distribution of drugs within solid tumors presents a long-standing barrier for efficient cancer therapies. Tumors are highly resistant to diffusion, and the lack of blood and lymphatic flows suppresses convection. Prolonged, continuous intratumoral drug delivery from a miniature drug source offers an alternative to both systemic delivery and intratumoral injection. Presented here is a model of drug distribution from such a source, in a multistep process. At delivery onset the drug mainly affects the closest surroundings. Such ‘priming’ enables drug penetration to successive cell layers. Tumor ‘void volume’ (volume not occupied by cells) increases, facilitating lymphatic perfusion. The drug is then transported by hydraulic convection downstream along interstitial fluid pressure (IFP) gradients, away from the tumor core. After a week tumor cell death occurs throughout the entire tumor and IFP gradients are flattened. Then, the drug is transported mainly by ‘mixing’, powered by physiological bulk body movements. Steady state is achieved and the drug covers the entire tumor over several months. Supporting measurements are provided from the LODER™ system, releasing siRNA against mutated KRAS over months in pancreatic cancer in-vivo models. LODER™ was also successfully employed in a recent Phase 1/2 clinical trial with pancreatic cancer patients. Impact Journals LLC 2015-09-22 /pmc/articles/PMC4741846/ /pubmed/26416413 Text en Copyright: © 2015 Shemi et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Shemi, Amotz
Khvalevsky, Elina Zorde
Gabai, Rachel Malka
Domb, Abraham
Barenholz, Yechezkel
Multistep, effective drug distribution within solid tumors
title Multistep, effective drug distribution within solid tumors
title_full Multistep, effective drug distribution within solid tumors
title_fullStr Multistep, effective drug distribution within solid tumors
title_full_unstemmed Multistep, effective drug distribution within solid tumors
title_short Multistep, effective drug distribution within solid tumors
title_sort multistep, effective drug distribution within solid tumors
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741846/
https://www.ncbi.nlm.nih.gov/pubmed/26416413
work_keys_str_mv AT shemiamotz multistepeffectivedrugdistributionwithinsolidtumors
AT khvalevskyelinazorde multistepeffectivedrugdistributionwithinsolidtumors
AT gabairachelmalka multistepeffectivedrugdistributionwithinsolidtumors
AT dombabraham multistepeffectivedrugdistributionwithinsolidtumors
AT barenholzyechezkel multistepeffectivedrugdistributionwithinsolidtumors